Halobetasol/tazarotene
| Combination of | |
|---|---|
| Ulobetasol propionate | Corticosteroid |
| Tazarotene | Retinoid |
| Clinical data | |
| Trade names | Duobrii |
| AHFS/Drugs.com | Multum Consumer Information |
| Routes of administration | Topical |
| Legal status | |
| Legal status | |
Halobetasol/tazarotene (Duobrii) is a topical combination drug used to treat plaque psoriasis. It combines 0.01% halobetasol propionate (a corticosteroid that reduces inflammation and suppresses the immune system) and 0.045% tazarotene (a retinoid that promotes normal skin cell turnover and has anti-inflammatory effects) in a lotion formulation.[2][3][4][5] It was approved as a prescription drug by the U.S. Food and Drug Administration (FDA) in April 2019[2][3][4][5] and by Health Canada in June 2020.[6][7]
References
[edit]- ^ "Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
- ^ a b "DUOBRII- halobetasol propionate and tazarotene lotion". DailyMed. 1 January 2020. Retrieved 15 January 2024.
- ^ a b Reddy V, Myers B, Yang EJ, Bhutani T (2020). "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults". Clinical, Cosmetic and Investigational Dermatology. 13: 391–398. doi:10.2147/CCID.S252426. PMC 7295208. PMID 32606876.
- ^ a b Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R (June 2021). "Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology". The Journal of Dermatological Treatment. 32 (4): 391–398. doi:10.1080/09546634.2019.1668907. PMID 31522563. S2CID 202582002.
- ^ a b Duffy, Steve (26 April 2019). "FDA Approves Unique Combination Topical Therapy for Plaque Psoriasis". MPR. Retrieved 16 January 2024.
- ^ Barry, Martin (15 June 2020). "Ottawa approves Bausch Health psoriasis drug to be produced in Laval". lavalnews.ca. Retrieved 16 January 2024.
- ^ "Voluntary compliance undertaking of Bausch Health, Canada Inc. to the Patented Medicine Prices Review Board". Government of Canada. 4 January 2023. Retrieved 16 January 2024.
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |